Ameritas Investment Partners’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Ameritas Investment Partners’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-939	Closed	-$124K	–	3108
2020 Q4	$124K	Hold	939	–	–	0.01%	1445
2020 Q3	$47K	Hold	939	–	–	﹤0.01%	1886
2020 Q2	$45K	Hold	939	–	–	﹤0.01%	1902
2020 Q1	$46K	Hold	939	–	–	﹤0.01%	1716
2019 Q4	$54K	Hold	939	–	–	﹤0.01%	1877
2019 Q3	$34K	Hold	939	–	–	﹤0.01%	2113
2019 Q2	$29K	Sell	939 -401	-30%	-$10.9K	﹤0.01%	2232
2019 Q1	$31K	Buy	1,340 +840	+168%	+$13.5K	﹤0.01%	2145
2018 Q4	$7K	Hold	500	–	–	﹤0.01%	2799
2018 Q3	$5K	Buy	+500	New	+$8.22K	﹤0.01%	2958

Ameritas Investment Partners's EIDX Position: Q1 2021 in Review

Ameritas Investment Partners sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 939 shares — an estimated $124K sold.

Ameritas Investment Partners first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $124K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Ameritas Investment Partners reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Ameritas Investment Partners sold 939 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $124K.
Ameritas Investment Partners first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Ameritas Investment Partners's Eidos Therapeutics, Inc. Common Stock position peaked at $124K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Ameritas Investment Partners's 13F filing for Q1 2021, filed 14 May 2021.